About Evogene (NASDAQ:EVGN)
Evogene Ltd. (Evogene) is a biotechnology company for the improvement of crop productivity. The Company is engaged in developing seed traits for improved yield and abiotic stress tolerance, seed traits for biotic stress resistance, herbicides and bio-stimulants. The Company operates a seed business under its subsidiary Evofuel Ltd. (Evofuel). It operates through two segments. Its Evogene segment develops seed traits, ag-chemical products, and ag-biological products to improve plant performance. The Company's Evofuel segment develops species of the castor bean plant for second generation feedstock for biofuel and other industrial uses. Its Crop Enhancement (CE) division is developing two types of products: CE seed traits, are seed traits having improved yield and abiotic stress tolerance, and ag-biologicals, which focuses on microbial-based bio-stimulants. The Company's Crop Protection (CP) division is developing two types of products: CP seed traits and ag-chemicals.
Industry, Sector and Symbol:
- Industry: Agricultural Biotechnology
- Sub-Industry: N/A
- Sector: Medical
- Symbol: NASDAQ:EVGN
- CUSIP: N/A
- Web: www.evogene.com
- Current Ratio: 17.67%
- Quick Ratio: 17.67%
Sales & Book Value:
- Annual Sales: $6.54 million
- Price / Sales: 15.08
- Book Value: $3.43 per share
- Price / Book: 1.12
- Trailing EPS: ($0.83)
- Net Income: ($19,590,000.00)
- Net Margins: -462.56%
- Return on Equity: -24.88%
- Return on Assets: -22.64%
- Employees: 240
- Outstanding Shares: 25,750,000
Frequently Asked Questions for Evogene (NASDAQ:EVGN)
What is Evogene's stock symbol?
Evogene trades on the NASDAQ under the ticker symbol "EVGN."
How were Evogene's earnings last quarter?
Evogene Ltd. (NASDAQ:EVGN) issued its quarterly earnings results on Thursday, August, 11th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by $0.07. The biotechnology company had revenue of $3.82 million for the quarter, compared to analysts' expectations of $5.36 million. Evogene had a negative return on equity of 24.88% and a negative net margin of 462.56%. View Evogene's Earnings History.
When will Evogene make its next earnings announcement?
Who are some of Evogene's key competitors?
Some companies that are related to Evogene include Nymox Pharmaceutical Corporation (NYMX), GTx (GTXI), OncoMed Pharmaceuticals (OMED), Intec Pharma (NTEC), Anavex Life Sciences Corp. (AVXL), CareDx (CDNA), Cogentix Medical (CGNT), Verona Pharma PLC American Depositary Share (VRNA), Signal Genetics (MGEN), Majesco Entertainment Company (COOL), Invuity (IVTY), Cellular Biomedicine Group (CBMG), iRadimed Corporation (IRMD), Quorum Health Corporation (QHC), Nivalis Therapeutics (ALPN), Viralytics (VRACY), SeaSpine Holdings Corporation (SPNE) and Cumberland Pharmaceuticals (CPIX).
Who are Evogene's key executives?
Evogene's management team includes the folowing people:
- Martin S. Gerstel, Chairman of the Board (Age 73)
- Ofer Haviv, President, Chief Executive Officer (Age 47)
- Alex Taskar, Chief Financial Officer
- Yuval Ben-Galim, Chief Operating Officer
- Hagai Karchi, Executive Vice President, Chief Technology Officer (Age 53)
- Amos Shachar, Vice President of Project Management (Age 39)
- Lea Slonim Bloom, Director of Administration & Human Resources (Age 43)
- Sarit Firon, Director
- Adina Makover, Director (Age 65)
- Leon Yehuda Recanati, Director (Age 67)
How do I buy Evogene stock?
Shares of Evogene can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Evogene's stock price today?
One share of Evogene stock can currently be purchased for approximately $3.83.
How big of a company is Evogene?
Evogene has a market capitalization of $98.1 million and generates $6.54 million in revenue each year. The biotechnology company earns ($19,590,000.00) in net income (profit) each year or ($0.83) on an earnings per share basis. Evogene employs 240 workers across the globe.
How can I contact Evogene?
Evogene's mailing address is 13 GAD FEINSTEIN STREET, REHOVOT L3, 7612002. The biotechnology company can be reached via phone at 972-8931-1900 or via email at [email protected]
MarketBeat Community Rating for Evogene (NASDAQ EVGN)MarketBeat's community ratings are surveys of what our community members think about Evogene and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Evogene (NASDAQ:EVGN) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Analysts' Consensus Price Target: ||N/A|
Consensus Price Target History for Evogene (NASDAQ:EVGN)
Analysts' Ratings History for Evogene (NASDAQ:EVGN)
(Data available from 11/18/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|8/17/2016||Credit Suisse Group||Lower Price Target||Outperform||$19.00 -> $10.00||N/A|
|11/19/2015||Piper Jaffray Companies||Lower Price Target||Neutral||$12.00 -> $8.00||N/A|
Earnings History and Estimates Chart for Evogene (NASDAQ:EVGN)
Earnings History by Quarter for Evogene (NASDAQ EVGN)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/11/2016||Q2||($0.11)||($0.18)||$5.36 million||$3.82 million||View||Listen|
|5/19/2016||Q1||($0.11)||($0.13)||$2.70 million||$2.00 million||View||Listen|
|3/1/2016||Q415||($0.17)||($0.22)||$3.90 million||$2.46 million||View||N/A|
|11/18/2015||Q315||($0.15)||($0.13)||$3.50 million||$3.31 million||View||Listen|
|8/5/2015||Q215||($0.19)||($0.20)||$4.40 million||$2.66 million||View||N/A|
|5/19/2015||Q115||($0.20)||($0.13)||$3.65 million||$2.70 million||View||Listen|
|11/10/2014||Q314||($0.10)||($0.17)||$4.20 million||$3.16 million||View||N/A|
|8/20/2014||Q214||($0.11)||($0.13)||$4.77 million||$3.85 million||View||N/A|
|5/7/2014||Q1 14||($0.13)||($0.09)||$5.40 million||$3.86 million||View||N/A|
|3/19/2014||Q413||($0.08)||($0.20)||$4.95 million||$4.41 million||View||N/A|
Earnings Estimates for Evogene (NASDAQ:EVGN)
Current Year EPS Consensus Estimate: $-0.74 EPS
Next Year EPS Consensus Estimate: $-0.44 EPS
Dividend History for Evogene (NASDAQ:EVGN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Evogene (NASDAQ EVGN)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Evogene (NASDAQ:EVGN)
Latest Headlines for Evogene (NASDAQ EVGN)
Evogene (NASDAQ EVGN) Chart for Saturday, November, 18, 2017